GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biofrontera AG (XTER:B8F) » Definitions » Equity-to-Asset

Biofrontera AG (XTER:B8F) Equity-to-Asset : 0.58 (As of Sep. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Biofrontera AG Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Biofrontera AG's Total Stockholders Equity for the quarter that ended in Sep. 2023 was €13.89 Mil. Biofrontera AG's Total Assets for the quarter that ended in Sep. 2023 was €24.02 Mil. Therefore, Biofrontera AG's Equity to Asset Ratio for the quarter that ended in Sep. 2023 was 0.58.

The historical rank and industry rank for Biofrontera AG's Equity-to-Asset or its related term are showing as below:

XTER:B8F' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.84   Med: 0.29   Max: 0.75
Current: 0.58

During the past 13 years, the highest Equity to Asset Ratio of Biofrontera AG was 0.75. The lowest was -0.84. And the median was 0.29.

XTER:B8F's Equity-to-Asset is ranked worse than
50.23% of 1087 companies
in the Drug Manufacturers industry
Industry Median: 0.59 vs XTER:B8F: 0.58

Biofrontera AG Equity-to-Asset Historical Data

The historical data trend for Biofrontera AG's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biofrontera AG Equity-to-Asset Chart

Biofrontera AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.42 0.17 0.13 0.75 0.62

Biofrontera AG Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.56 0.62 0.63 0.62 0.58

Competitive Comparison of Biofrontera AG's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera AG's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biofrontera AG's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biofrontera AG's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Biofrontera AG's Equity-to-Asset falls into.



Biofrontera AG Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Biofrontera AG's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Equity to Asset (A: Dec. 2022 )=Total Stockholders Equity/Total Assets
=20.336/32.725
=0.62

Biofrontera AG's Equity to Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

Equity to Asset (Q: Sep. 2023 )=Total Stockholders Equity/Total Assets
=13.887/24.019
=0.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biofrontera AG  (XTER:B8F) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Biofrontera AG Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Biofrontera AG's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Biofrontera AG (XTER:B8F) Business Description

Traded in Other Exchanges
Address
Hemmelrather Weg 201, Leverkusen, NW, DEU, 51377
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.

Biofrontera AG (XTER:B8F) Headlines

No Headlines